Given that MDM2 is the major E3 ubiquitin ligase that dictates the p53 level in cells, a better understanding of how MDM2 catalyzes the transfer of ubiquitin would provide the ground for the development of novel strategies for therapeutic activation of p53 in cancer. The gene discussed is MDM2; the disease is cancer.